Tumours that had previously received only cetuximab immediately begun to regrow while those that had been treated with EGFR and MEK inhibitors remained undetectable or showed marginal growth by week 15 (Fig. 3a,b and Supplementary Data 1). The gene discussed is EGFR; the disease is neoplasm.